课题基金 / 基金详情

STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES

STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES
复发性生殖器疱疹患者口服洛布卡韦的研究
批准号：
6566712
负责人：
STEPHEN K TYRING
金额：
$27.93万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
项目状态：
已结题
起止时间：
2001-12-01 至 2002-11-30
来源：
https://reporter.nih.gov/project-details/6566712
关键词：
antiviral agents clinical research clinical trial phase I dosage drug screening /evaluation genital herpes human subject human therapy evaluation microorganism disease chemotherapy oral administration placebos relapse /recurrence volunteer

项目摘要

项目成果

STEPHEN K TYRING的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We will test the efficacy and safety of a new antiviral drug, lobucavir, from Bristol Myers Squibb, in immunocompetent subjects with recurrent genital herpes infections. Volunteers in this randomized, double-blind, placebo-controlled study will receive one of three doses of lobucavir or placebo twice daily for five days. Follow-up visits to the clinic will continue until the genital herpes lesions are completely healed. Lobucavir has proven a potent antiviral in tissue culture and animal model studies. Therefore, the findings from these studies may help in developing a genital herpes treatment that will hasten healing of lesions and reduce the severity or duration of the pain and discomfort associated with the infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic Resistance to Oncogenic Human Papillomaviruses
Genetic Resistance to Oncogenic Human Papillomaviruses
ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS
海外基金